Analysis of the metabolic syndrome improvement with the orexin receptor antagonist

Analysis of the metabolic syndrome improvement with the orexin receptor antagonist - Effect of orexin receptor antagonist on metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027445

Enrollment

Registered

2017-06-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome with insomnia

Interventions

Orexin receptor antagonist (suvorexant) 20mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients satisfying metabolic syndrome criteria with insomnia

Exclusion criteria

Exclusion criteria: The patients appeared harmful effect of suvorexant The patients prescribed with CYP3A inhibitory drugs

Design outcomes

Primary

Measure	Time frame
We will evaluate whether the patients fill the criteria of MS 6 months after suvorexant treatment. MS criteria is satisfied with abdominal circumference is higher than 85cm in male and 90cm in female, and with higher than two items in follows: (1) Dyslipidemia: triglyceride is higher than 150mg/dl and/or HDL cholesterol is lower than 40mg/dl. (2) Hypertension: systolic blood pressure is higher than 130mmHg and/or diastolic blood pressure is higher than 85mmHg. (3) Impaired glucose tolerance: fasting blood glucose is higher than 110mg/dl.	—

Measure

Time frame

We will evaluate whether the patients fill the criteria of MS 6 months after suvorexant treatment. MS criteria is satisfied with abdominal circumference is higher than 85cm in male and 90cm in female, and with higher than two items in follows: (1) Dyslipidemia: triglyceride is higher than 150mg/dl and/or HDL cholesterol is lower than 40mg/dl. (2) Hypertension: systolic blood pressure is higher than 130mmHg and/or diastolic blood pressure is higher than 85mmHg. (3) Impaired glucose tolerance: fasting blood glucose is higher than 110mg/dl.

—

Countries

Japan

Contacts

Public ContactMITSURU NISHIYAMA

Kochi Medical School, Kochi University Department of Endocrinology, Metabolism & Nephrology

nisiyamm@kochi-u.ac.jp088-880-2343

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026